ZAI LAB LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.4 USD | -2.66% |
|
-3.39% | -29.02% |
| Sales 2024 * | 389M 30.65B | Sales 2025 * | 617M 48.6B | Capitalization | 1.92B 152B |
|---|---|---|---|---|---|
| Net income 2024 * | -277M -21.81B | Net income 2025 * | -130M -10.23B | EV / Sales 2024 * | 3.56 x |
| Net cash position 2024 * | 538M 42.35B | Net cash position 2025 * | 275M 21.68B | EV / Sales 2025 * | 2.67 x |
| P/E ratio 2024 * |
-7.06
x | P/E ratio 2025 * |
-18.2
x | Employees | 2,175 |
| Yield 2024 * |
-
| Yield 2025 * |
1.03% | Free-Float | 9.91% |
More Fundamentals
* Assessed data
More news
Latest transcript on Zai Lab Limited
More recommendations
More press releases
More news
| 1 day | -2.66% | ||
| 1 week | -3.39% | ||
| Current month | +22.78% | ||
| 1 month | +37.88% | ||
| 3 months | -6.01% | ||
| 6 months | -29.63% | ||
| Current year | -29.02% |
1 week
19.31
21.82
1 month
14.4822.35
Current year
13.4827.87
1 year
13.4837.92
3 years
13.48181.92
5 years
13.48193.54
10 years
13.48193.54
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Du
CEO | Chief Executive Officer | 59 | 31/03/14 |
Ya jing Chen
DFI | Director of Finance/CFO | 56 | 31/08/21 |
Joshua Smiley
PSD | President | 54 | 31/07/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John D. Diekman
BRD | Director/Board Member | 81 | 31/12/16 |
Peter Wirth
BRD | Director/Board Member | 73 | 31/12/16 |
Lonnie Moulder
BRD | Director/Board Member | 66 | 31/12/18 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.29% | 4 M€ | -27.92% | ||
| 1.04% | 2 M€ | -12.23% | - | |
| 0.75% | 96 M€ | -.--% | - | |
| 0.27% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/05/24 | 19.4 | -2.66% | 463,667 |
| 16/05/24 | 19.93 | -4.41% | 565,888 |
| 15/05/24 | 20.85 | -3.25% | 631,179 |
| 14/05/24 | 21.55 | +0.14% | 397,885 |
| 13/05/24 | 21.52 | +7.17% | 654,977 |
Delayed Quote Nasdaq, May 17, 2024 at 09:00 pm
More quotes
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
Sector
Pharmaceuticals
Calendar
23/05/2024
- J.P. Morgan Global China Summit
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
19.4
USD
Average target price
51.37
USD
Spread / Average Target
+164.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.02% | 1.92B | |
| -2.39% | 90.45B | |
| +3.68% | 41.45B | |
| -10.90% | 33.57B | |
| +58.05% | 25.73B | |
| -19.56% | 14.73B | |
| -9.06% | 12.82B | |
| -11.34% | 11.7B | |
| -43.53% | 11.44B | |
| +3.75% | 8.79B |
- Stock Market
- Equities
- ZLAB Stock
